Expert insights guide relapsed/refractory CLL therapy sequencing, weighing prior response, BTK inhibitor intolerance vs resistance, and venetoclax duration to tailor next-line choices.
Jennifer J. Huang, MD, PhD
Advertisement
Articles by Jennifer J. Huang, MD, PhD
Expert insights guide relapsed/refractory CLL therapy sequencing, weighing prior response, BTK inhibitor intolerance vs resistance, and venetoclax duration to tailor next-line choices.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Key Questions on ADC Selection, Sequencing, and Toxicity Management Across Breast Cancer Subtypes
2
Subcutaneous Toripalimab Plus Disitamab Vedotin sNDA Is Accepted in China for HER2-Expressing Urothelial Cancer
3
Broadening HER2-Mutated NSCLC Data Support First-Line Zongertinib Followed by T-DXd
4
Lirafugratinib Associated With More Mucocutaneous AEs After Prior ICIs in FGFR2-Altered CCA and Other Solid Tumors
5